Giles Coghlan LLB, Lth, MA
Financial Source
The news last week that Johnson and Johnson’s vaccine caused blood clots sent a shiver down markets mid-week. However, once the headline was digested it was realized that there were still vaccine alternatives to replace J&J’s even if there was a delay in the rollout.
White house confirms vaccine coverage
This was underlined by White House COVID Coordinator Zients who stated last week that there is plenty of vaccine supply in the system, even without J&J’s COVID-19 vaccine and that the US Gov’t is doing everything it can to accelerate the Pfizer and Moderna vaccines.
Ok, panic over. The dip was bought on the headline last week.
However, it is interesting to note that in stark contrast to the inflation fears, which came to nothing last week, the market remains laser-focused on the vaccine rollout. So, right now, vaccines matter most.
One interesting headline from last week that could be lost in the mix is the fact that Novavax will be taking part in an Oxford University study comparing mixed COVID-19 vaccine combinations from different manufacturers. The idea of the study is to explore any potential possibility there is of mixing doses. This will be extremely helpful if a ‘mix&max’ combination is possible and should help speed up the vaccination process and reward manufacturers who can supply the most quickly. One report to look out for as it could give risk assets a positive boost if the study proves positive. The current levels of people who have received at least one vaccine can be seen here below.
The key impact of any significant delay/problem in the vaccination program would be a sell-off in equity markets.
Our products and commentary provides general advice that do not take into account your personal objectives, financial situation or needs. The content of this website must not be construed as personal advice.
Recommended Content
Editors’ Picks
EUR/USD off highs, back to the 1.1050 area ahead of Fed Minutes
EUR/USD keeps its bullish stance well in place, adding to Tuesday's uptick and retesting the vicinity of the 1.1100 neighbourhood on the back of the intense sell-off in the Greenback, all amid steady concerns over the impact of the China-US trade war.
GBP/USD eases to daily lows near 1.2750, USD picks up pace
The recovery attempt in the US Dollar is now prompting GBP/USD to give away part of the earlier advance past 1.2800 the figure and recedes to the mid-1.2700s in a context still widely favourable to the risk complex.
Gold climbs further, retargets $3,100
Gold preserves its bullish momentum and approaches the $3,100 level per troy ounce on Wednesday, underpinned by the steady safe-haven demand in response to trade tensions between the US and China.
Fed Minutes to offer clues on rate cut outlook amid tariff uncertainty
The eagerly awaited minutes from the US Fed’s March 18-19 monetary policy meeting are set for release on Wednesday at 18:00 GMT. During the gathering, policymakers agreed to keep the Fed Funds Target Range (FFTR) unchanged at 4.25%-4.50%.
Tariff rollercoaster continues as China slapped with 104% levies
The reaction in currencies has not been as predictable. The clear winners so far remain the safe-haven Japanese yen and Swiss franc, no surprises there, while the euro has also emerged as a quasi-safe-haven given its high liquid status.
The Best brokers to trade EUR/USD
SPONSORED Discover the top brokers for trading EUR/USD in 2025. Our list features brokers with competitive spreads, fast execution, and powerful platforms. Whether you're a beginner or an expert, find the right partner to navigate the dynamic Forex market.